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One-sentence summary: Sensory neurons expressing the GPCR Mrgprd mediate the effects of a bioactive 
lipid to cause abdominal pain. 
 
Editor’s summary: 
Inducing pain in IBS 
A symptom of irritable bowel syndrome (IBS) that accompanies altered bowel function is abdominal pain. 
Noting that various polyunsaturated fatty acids (PUFAs) are implicated in modulating inflammation in 
patients with IBS, Bautzova et al. found that the abundance of the PUFA 5-oxoETE was selectively 
increased in colonic biopsies from patients with a subtype of IBS characterized by constipation (IBS-C). 5-
oxoETE increased pain sensitivity in mice without eliciting inflammation and stimulated both mouse and 
human dorsal root ganglia neurons expressing the GPCR Mrgprd. Knockdown of Mrgprd in mice reduced 
the percentage of neurons that responded to 5-oxoETE and decreased pain sensitivity, suggesting that this 
PUFA may mediate abdominal pain in patients with IBS-C. 
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 Abstract 
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that is characterized by 
chronic abdominal pain concurrent with altered bowel habit. Polyunsaturated fatty acid (PUFA) 
metabolites are increased in abundance in IBS and are implicated in the alteration of sensation to 
mechanical stimuli, which is defined as visceral hypersensitivity. We sought to quantify PUFA 
metabolites in IBS patients and evaluate their role in pain. Quantification of PUFA metabolites by 
mass spectrometry in colonic biopsies showed an increased abundance of 5-oxo-eicosatetraenoic 
acid (5-oxoETE) only in biopsies taken from patients with IBS with predominant constipation 
(IBS-C). Local administration of 5-oxoETE to mice induced somatic and visceral hypersensitivity 
to mechanical stimuli without causing tissue inflammation. We found that 5-oxoETE directly acted 
on both human and mouse sensory neurons as shown by lumbar splanchnic nerve recordings and 
Ca2+-imaging of dorsal root ganglia (DRG) neurons. We showed that 5-oxoETE selectively 
stimulated nonpeptidergic, isolectin B4 (IB4)-positive DRG neurons through a phospholipase C 
(PLC)– and pertussis toxin–dependent mechanism, suggesting that the effect was mediated by a G 
protein–coupled receptor (GPCR). The MAS-related GPCR D (Mrgprd) was found in mouse 
colonic DRG afferents and was identified as being implicated in the noxious effects of 5-oxoETE. 
Together, these data suggest that 5-oxoETE, a potential biomarker of IBS-C, induces somatic and 
visceral hyperalgesia without inflammation in an Mrgprd-dependent manner. Thus, 5-oxoETE 
may play a pivotal role in the abdominal pain associated with IBS-C. 
 
Introduction 
Irritable bowel syndrome (IBS) is a functional bowel disorder in which recurrent abdominal pain 
is associated with a change in bowel habit, typically constipation (IBS-C), diarrhea (IBS-D), or a 
mixed (constipation and diarrhea) bowel habit (IBS-M) (1). IBS is a common disorder in Western 
populations, which affects around 11% of the global population (2), with a higher prevalence in 
women than in men (1). Although the aetiology of IBS remains unclear, low-grade inflammation 
has been widely described in this disorder, with several fundamental studies implicating 
proinflammatory molecules in the pathophysiology of IBS symptoms (3). We previously showed 
that the amounts of several polyunsaturated fatty acid (PUFA) metabolites, also defined as 
bioactive lipids, are statistically significantly altered in biopsy samples from patients with IBS 
compared to those in samples from healthy controls (4). This is in agreement with previous studies 
focused on the prostanoid subtype of PUFA metabolites (5-7). 
 
The functional relationship between PUFAs and pain has been the subject of many studies (8). 
Both basic and clinical studies have revealed that a dietary intake of n-3 series PUFAs results in a 
reduction in pain associated with rheumatoid arthritis (9, 10), dysmenorrhea (11), inflammatory 
bowel disease (12), and neuropathy (13), whereas n-6 series PUFAs are high in abundance in 
patients with chronic pain, including IBS patients (4, 14, 15). The n-3 PUFA metabolites, such as 
resolvins (Rvs), are analgesic in multiple pain models, an effect attributed to inhibition of certain 
transient receptor potential (TRP) channels (16). For example, RvE1 specifically inhibits TRPV1 
signaling (17), whereas RvD1 attenuates the function of TRPA1 and TRPV4 (18) and RvD2 
inhibits TRPV1 and TRPA1 activity (19). These effects have been observed with other types of n-
3 PUFAs, such as maresin 1 (Mar1), which also has inhibitory effects on TRPV1 channel function 
(20) and reduces pain. The quantification of Rvs in the knee synovia of patients suffering from 
inflammatory arthritis suggests that synthesis of specialized proresolving mediators (SPMs) at the 
site of inflammation may be a mechanism of endogenous pain relief in humans. In contrast, n-6 
PUFA metabolites are pro-nociceptive by stimulating nerve fibers through the activation of 
immune cells (21, 22). Nonetheless, several n-6 PUFA metabolites, such as thromboxane A2 
(TXA2), PGE2, leukotriene B4 (LTB4), and PGD2, can directly stimulate sensory nerve fibers (23-
26). However, some n-6 PUFA metabolites, such as lipoxins, can inhibit pain (27). Consistent with 
the role of TRP channels in the transduction of noxious stimuli, we previously showed a correlation 
between PUFA metabolites and TRP channel activation, particularly for the TRPV4 agonist 5,6-
epoxyeicosatrienoic acid (5,6-EET) and pain intensity in IBS-D patients (4). Furthermore, PUFA 
metabolites from colonic biopsies of IBS-C patients induced Ca2+ influx in sensory neurons 
independently of TRPV4, suggesting that the PUFA metabolites produced in IBS-C and IBS-D 
are distinct (4). Thus, the aim of this study was to identify algogenic PUFA metabolites specifically 
produced in IBS-C patients and decipher the mechanism by which they may activate sensory 
nerves. Herein, we showed that 5-oxoETE, an n-6 PUFA subtype selectively increased in 
abundance in colonic tissues from IBS-C patients, induced hypersensitivity in a manner dependent 
on the G protein–coupled receptor (GPCR) Mrgprd. 
 
Results 
5-oxoETE is increased in abundance in colonic biopsies from IBS-C patients 
PUFA metabolites were quantified in colonic biopsies from IBS patients and healthy controls 
(HCs) using liquid chromatography/tandem mass spectrometry (LC-MS/MS). Hierarchical 
clustering of PUFA metabolite amounts quantified in biopsies (pg/mg of protein) was used to 
reveal the main differences between HCs, IBS-M, IBS-C, and IBS-D patients (Fig. 1A). PUFA 
metabolites formed five different clusters. The first cluster contained products of arachidonic acid 
metabolism (PGE2, TXB2, 5,6-EET, and 14,15-EET), eicosapentaenoic acid metabolism (18-
HEPE, LtB5, and PGE3) and protectin Dx (PDx). Metabolites belonging to this first cluster were 
most abundant in biopsies from IBS-D patients (Fig. 1A). Note that TxB2, PGE2, and 5,6-EET 
were only increased in biopsies of IBS-D patients (fig. S1). In contrast, TxB2 was decreased in 
abundance in biopsies from IBS-C patients (fig. S1). The second cluster discriminated only 5-
oxoETE, which was substantially increased in biopsies from IBS-C patients (Fig. 1, A and B). The 
concentrations of 7-MaR1 and 15dPGJ2, which delineated a third cluster, showed an increasing 
trend, but did not reach statistical significance in biopsies from any group of IBS patients (fig. S2). 
The fourth cluster, grouping most of the lipoxygenase-derived metabolites, was decreased in 
biopsies from all subtypes of IBS patients compared to HCs (Fig. 1A). 15-HETE, 5-HETE, 12-
HETE, 14-HDoHE, and 17-HDoHE were statistically significantly decreased in abundance in all 
IBS patients (fig. S2). In addition, 12-HETE was statistically significantly decreased in abundance 
in biopsies from IBS-C patients (fig. S1). The metabolites included in the fifth cluster were reduced 
in amount only in biopsies from IBS-C and IBS-D patients (Fig. 1A). RvD1 and RvD2 were not 
detectable in any colonic biopsies. Thus, among all of the PUFA metabolites quantified in colonic 
biopsies from IBS patients, 5-oxoETE was the only one to be statistically significantly increased 
in IBS-C patients compared to the other IBS subtypes (Fig. 1B) and thus warranted further 
investigation. 
 
Local administration of 5-oxoETE induces somatic and visceral hyperalgesia without 
inflammation 
Because PUFA metabolites can stimulate the immune system, directly stimulate nerves, or both, 
we first assessed the effect of 5-oxoETE on pain and inflammation processes in vivo. In a first set 
of experiments, 5-oxoETE was subcutaneously injected into the paws of mice and the paw-
withdrawal threshold to mechanical stimuli was estimated using calibrated von Frey filaments. 
The time course of mechanical hypersensitivity of the mice that received 5-oxoETE was compared 
with that of mice injected with vehicle (HBSS). Basal mechanical sensitivity, measured in the paw 
before injection, was identical in both groups of mice (Fig. 2A). Injection of 5-oxoETE into the 
hind paws resulted in a decrease in the paw-withdrawal threshold (Fig. 2A) and was observed from 
15 min up to 2 hours after 5-oxoETE injection, with maximal reduction at 30 min. The mechanical 
pain threshold was decreased in a dose-dependent manner 30 min after 5-oxoETE administration 
with an EC50 of 0.6 µM (Fig. 2B). In addition, paw edema formation and histological analysis were 
investigated to verify whether injection of 5-oxoETE induced an inflammatory process. Injection 
of 5-oxoETE into the hind paw did not induce paw edema (fig. S3). Moreover, histological analysis 
of paw tissue did not reveal any sign of inflammation. Similarly, neither tissue disruption nor 
cellular infiltration was observed even 6 hours after the injection of 100 µM 5-oxoETE (Fig. 2C). 
Thus, at the somatic level, 5-oxoETE increased paw sensitivity to mechanical stimulation without 
inducing a quantifiable inflammatory reaction. 
 
Intracolonic administration of 5-oxoETE resulted in an increased intensity of abdominal 
contractions in response to colorectal distension (Fig. 2D). Moreover, the increased intensity of 
abdominal contractions was observed in response to both innocuous (15 mmHg; allodynia) and 
noxious (30 to 60 mmHg; hyperalgesia) stimuli 30 min after 5-oxoETE treatment (Fig. 2D). 
Intracolonic treatment with vehicle (40% ethanol) did not alter abdominal contraction response 
(Fig. 2D). As was observed after the subcutaneous injection of hind paws, intracolonic 
administration of 5-oxoETE did not induce inflammation of the colon. Colonic inflammation was 
assessed by macroscopic scoring and myeloperoxidase activity, which were not increased by 5-
oxoETE administration when compared to vehicle (fig. S3). Moreover, histological analysis did 
not reveal intestinal wall thickening, leukocyte infiltration into the lamina propria, the presence 
of ulceration, or goblet cell depletion (Fig. 2E). Thus, in vivo local administration of 5-oxoETE 
induced visceral hyperalgesia in the absence of inflammation, thus suggesting a direct effect on 
nociceptors. 
 
5-oxoETE stimulates visceral and somatic nociceptors: translation to human DRG 
To confirm a direct effect of 5-oxoETE on sensory nerve terminals innervating the colon, we 
examined its effects upon action potential firing in mouse colonic nociceptors. Specifically, we 
made teased-fiber electrophysiological recordings from the lumbar splanchnic nerve innervating 
the distal colon, which is primarily composed of colonic nociceptors with endings on serosal blood 
vessels penetrating the colon and in the mesentery. On defined populations of nociceptors with 
receptive fields isolated in flat sheet preparations, we applied 100 µM 5-oxoETE to a small 
chamber placed directly over the receptive field. 5-oxoETE stimulated action potential firing 
greater than vehicle in 38% of colonic nociceptor endings assessed (Fig. 3). In a second set of 
experiments, we determined the effect of 5-oxoETE on Ca2+ mobilization in primary cultures of 
neurons from mouse DRGs. In preliminary experiments performed with a working solution 
containing Ca2+ and Mg2+, we observed a transient increase in the concentration of intracellular 
Ca2+ ([Ca2+]i) (fig. S4). To determine whether this transient increase was the consequence of 
intracellular Ca2+ release or influx of external Ca2+, experiments were performed without Ca2+ and 
Mg2+ in the extracellular solution. Even without Ca2+ in the extracellular compartment, 5-oxoETE 
evoked a transient increase in [Ca2+]i that was maximal after 10 to 20 s and declined thereafter 
(Fig. 4A). The mobilization of intracellular Ca2+ by 5-oxoETE was concentration-dependent (Fig. 
4B). Similarly, 5-oxoETE induced an increase in [Ca2+]i and the percentage of responding neurons 
in a concentration-dependent manner in human primary sensory neurons (Fig. 4C). Thus, our data 
suggest that 5-oxoETE directly activates colonic DRG neurons from mice, as well as human 
sensory neurons, inducing an increase nociceptor firing (Fig. 3) and in [Ca2+]i (Fig. 4). 
 
Because 5-oxoETE induced somatic pain without inflammation in vivo, we hypothesised that 5-
oxoETE predominantly activates IB4+ sensory neurons, which do not release neuropeptides 
involved in neurogenic inflammation. To assess our hypothesis, we labelled mouse sensory 
neurons with isolectin B4 and treated the with 10 µM 5-oxoETE in the absence of extracellular 
Ca2+. We found that 5-oxoETE induced an increase in [Ca2+]i in >50% of the IB4-positive neurons, 
but not in IB4-negative neurons (Fig. 4D). To decipher the intracellular pathway responsible for 
the intracellular Ca2+ mobilization by 5-oxoETE, we pretreated mouse sensory neurons with 
pertussis toxin (PTX), which inhibits Gi family G proteins, or the PLC inhibitor U73122. In 
neurons pretreated with PTX (250 ng/ml), the increase in [Ca2+]i induced by 5-oxoETE was 
statistically significantly decreased (Fig. 4E). Pre-treatment of sensory neurons with 10 µM 
U73122 also inhibited the increase in [Ca2+]i induced by 5-oxoETE (Fig. 4E). Thus, these data 
suggest that 5-oxoETE directly stimulates IB4-positive sensory neurons through a Gi/o- and Gq-
coupled GPCR. 
 
5-oxoETE activates sensory neurons and induces visceral hypersensitivity through Mrgprd 
Because we found that 5-oxoETE specifically activated IB4+ sensory neurons through Gi- 
mediated signalling pathways, we focused our attention on the MAS-related G protein receptor D 
(Mrgprd), which couples to Gi/o and Gq proteins. The expression and function of Mrgprd in 
polymodal nociceptors innervating the skin is well established (28); however, for visceral tissues, 
this remains less clear. To comprehensively assess this, we retrogradely labelled sensory afferents 
from the colon using microinjection of Fast Blue (FB) in wild-type mice and MrgprdEGFP mice. 
Single-cell qRT-PCR analysis was performed on FB-expressing cells from the DRGs of WT mice. 
We were able to detect Mrgprd mRNA at some level in 40% (18/45) of the FB-labelled sensory 
neurons projecting to the colon through the splanchnic nerve originating from the thoracolumbar 
(T10-L1) DRG (Fig. 5A). We detected Trpv1 mRNA in 82% (37/45) of cells, with 41% (15/37) 
of the Trpv1-positive neurons also expressing Mrgprd mRNA (Fig. 5A). Immunohistochemistry 
was performed on the T13 DRG from the MrgprdEGFP-expressing mice to determine the incidence 
of GFP expression and the peptidergic marker calcitonin gene-related peptide (CGRP) in FB-
labelled cells, which revealed two distinct non-overlapping populations (Fig. 5B). Consistent with 
previous studies, those sensory neurons labelled from the colon with the retrograde tracer Fast-
Blue were predominantly CGRP-positive (~70%). In contrast, GFP immunoreactivity was 
observed in a restricted subset of colonic sensory neurons, accounting for only 7% of FB-labelled 
cells (Fig. 5B and Table 2). Of the 274 FB+ cells assessed, only one cell co-expressed both Mrgprd 
and CGRP. Those neurons projecting to the viscera represented ~10% of the total population of 
T10-L1 DRG neurons. Thus, only a very small population (between less than 1% and 4%) of T10-
L1 DRG neurons are likely to be both colon-projecting and Mrgprd-positive. 
 
In experiments using an antibody against Mrgprd, we observed infrequent, yet reproducible, co-
localisation of Mrgprd with PGP9.5 in the colon sections of 6 WT mice of 10 that were assessed 
(fig. S5). Note that Mrgprd immunoreactivity was not observed in the colons of Mrgprd-deficient 
mice (fig. S6). The expression of Mrgprd in human sensory neurons was also assessed. We found 
that Mrgprd immunoreactivity was present in 22% of human T11 DRG neurons (Fig. 5C), which 
also co-expressed the pan-neuronal marker PGP9.5. In a culture of human sensory neurons, 20% 
of PGP9.5-positive neurons showed Mrgprd immunoreactivity (Fig. 5D). 
 
To demonstrate the role of Mrgprd in 5-oxoETE–induced neuronal firing, we knocked it down by 
transducing primary cultures of mouse sensory DRG neurons with a recombinant lentivirus 
expressing a shRNA directed against Mrgprd and the gene reporter red fluorescent protein (RFP). 
As a control, neurons were transduced with a lentivirus expressing a scrambled shRNA. As 
expected, the percentage of neurons that responded to 5-oxoETE was statistically significantly 
reduced in sensory neurons expressing the Mrgprd-specific shRNA compared to those neurons 
expressing the scrambled shRNA (Fig. 6A). Accordingly, application of 5-oxoETE on sensory 
neurons from Mrgprd-deficient mice had no greater effect than the application of HBSS alone 
(Fig. 6B). In contrast, treatment of sensory neurons from Mrgprd-deficient mice with a mixture of 
GPCR agonists (bradykinin, serotonin, and histamine, each at 10 µM), which was used as a 
positive control, induced an increase in [Ca2+]i (Fig. 6B). Reciprocally, 5-oxoETE induced a 
concentration-dependent increase in [Ca2+]i only in transfected, Mrgprd-expressing CHO cells 
(Fig. 6C). Finally, we assessed the sensitivity of Mrgprd-deficient mice to colorectal distension 30 
min after intracolonic administration of 10 µM 5-oxoETE. 5-oxoETE did not induce 
hypersensitivity in response to colorectal distension in Mrgprd-deficient mice (Fig. 6D). 
 
Discussion 
In this study, we showed that: (i) Concentrations of the PUFA metabolite 5-oxoETE were 
statistically significantly increased in biopsies from patients with IBS-C compared to biopsies from 
patients with other IBS subtypes or from HCs; (ii) 5-oxoETE induced somatic, as well as visceral, 
hyperalgesia, without promoting inflammation; (iii) 5-oxoETE activated both mouse and human 
sensory neurons; (iv) In mice, 5-oxoETE signaled in a manner dependent on Mrgprd. Together, 
these data suggest a role for 5-oxoETE and Mrgprd-expressing, IB4-positive sensory neurons in 
visceral hypersensitivity in IBS-C patients. 
 
Eicosanoids and docosanoids are the most important lipids implicated in inflammatory processes. 
They derive from the oxidation of twenty and twenty-two carbon PUFAs, respectively (29). 
Several PUFA metabolites are increased in abundance in the intestinal mucosa from patients with 
IBDs (including, TXA2, PGE2, LTB4, and PGD2), which induce visceral afferent fiber activation 
(23-26). Here, we showed that PGE2, 5,6-EET, and TXB2 were statistically significantly increased 
in abundance in the intestinal mucosa of IBS-D patients, whereas no alteration in PUFA 
metabolism was observed in patients with IBS-M. Furthermore, when lipid extracts from HCs and 
all IBS patients were compared, we observed a statistically significant decrease in the amounts of 
14-HDoHE and 17-HDoHE ,which are SPM precursors (30). Because SPMs possess an analgesic 
effect (31), the pain associated with IBS could be also the consequence of a decrease in SPM 
abundance, leading to sensory neuron activation. A complete characterization of the different 
SPMs produced by the metabolism of EPA, DHA, or DPA will be of interest for the 
characterization of bioactive lipids potentially linked with pain in IBS patients. 
 
We showed that the concentration of 5-oxoETE increased in only the colonic biopsies of IBS-C 
patients, highlighting its potential relevance as a new marker of this disease. 5-oxoETE, which 
derives from arachidonic acid (AA) metabolism, is produced by various inflammatory cells. In 
addition, it can also be synthesized from 5-HETE by stromal cells, possibly by transcellular 
biosynthesis (32). 5-oxoETE is formed by the oxidation of 5-HETE by 5-hydroxyeicosanoid 
dehydrogenase (5-HEDH) (33), a microsomal enzyme that is highly selective for 5S-HETE and 
requires NADP+ as a cofactor (34). 5-HEDH is found in neutrophils as well as in various other 
inflammatory and stromal cells, including monocytes (35), dendritic cells (36), and intestinal 
epithelial cells (37). 5-oxoETE is a potent chemoattractant for human and rat eosinophils and it 
indirectly promotes the survival of these cells (38). However, we observed no cellular infiltration 
either in the paw or intestinal mucosa of mice administered with 5-oxoETE. This discrepancy may 
be due to the rapid metabolism of 5-oxoETE in vivo (32) or the absence of other molecules, such 
as interleukin-5, which act in synergy to attract inflammatory cells during inflammatory processes 
or allergies (39). In our experiments, the injection of 5-oxoETE alone, without cofactors, could 
thus explain the absence of infiltration of tissues by polymorphonuclear cells. The formation of 5-
oxoETE requires NADP+ (40). Accordingly, oxidative stress associated with IBS-C (41) may 
improve the conversion rate of NADPH into NADP+ in epithelial cells, thereby resulting in the 
synthesis of greater amounts of 5-oxoETE. 
 
In a previous study, we reported that PUFA metabolites extracted from biopsies of IBS-C and IBS-
D patients triggered an increase in [Ca2+]i in primary sensory neurons, whereas those extracted 
from biopsies of IBS-M patients had no effect (4). We further identified the PUFA metabolite 5,6-
EET as a TRPV4 agonist with algogenic activity, specifically associated with IBS-D sub-group 
(4). By contrast, no PUFA metabolite with TRP agonist activity was found to be increased in 
abundance in IBS-C patient biopsies (4). Because we found that only 5-oxoETE was increased in 
biopsies of IBS-C patients, we hypothesized that this PUFA metabolite might be responsible for 
the activation of sensory neurons and hypersensitivity-associated with IBS-C. As previously 
reported in humans, 5-oxoETE may interact with the oxoeicosanoid receptor 1 (OXER1). 
However, there is no homologous OXE receptor in rodents (40). Because the observed 5-oxoETE-
–nduced increase in [Ca2+]i in mouse sensory neurons was inhibited by both a PLC inhibitor and 
PTX, we hypothesized that 5-oxoETE led to the activation of Gi/o/Gq-coupled GPCRs. Given 
that 5-oxoETE acted selectively on IB4+ sensory neurons, the targeted receptor should be 
specifically expressed on this neuronal subclass. Accordingly, we investigated the role of Mrgprd, 
a GPCR specifically expressed on IB4+ sensory neurons, which may be coupled to Gq proteins 
and to PTX–sensitive Gi/o proteins (42), and was previously reported as a key player in 
mechanical hypersensitivity (43-45). 
 
Stimulation of Mrgprd-positive neurons with -alanine, the prototypical agonist of Mrgprd, 
increases [Ca2+]i (46), as was observed here after 5-oxoETE treatment. Moreover, in a FLIPR 
(Fluorescent Imaging Plate Reader) assay developed for the simultaneous identification of Mrgprd 
agonists and antagonists, a PLC inhibitor completely blocked the FLIPR response to -alanine, 
whereas PTX treatment resulted in 50% reduction in [Ca2+]i (47). Again, similar results were 
obtained here in experiments with PTX or a PLC inhibitor to inhibit 5-oxoETE–induced activation 
of primary mouse sensory neurons. Using tissue from adult MrgprdEGFP mice stained with 
antibodies to GFP, a previous study showed that Mrgprd is expressed in non-peptidergic neurons 
that innervate the epidermis; however, Mrgprd-positive fibres were not observed in any other 
visceral organs, including both the small and large intestine (28). By contrast, numerous studies 
using different retrograde tracers have identified a minor population (20 to 26%) of IB4+ sensory 
neurons that innervate the colon (48-50). Indeed, a study also identified Mrgprd mRNA in colonic 
sensory neurons by single cell RNA-sequencing (51). To confirm the presence of both Mrgprd 
mRNA and Mrgprd protein in colonic sensory neurons in the present study, we applied a similar 
retrograde neurotracing approach using single-cell RT-qPCR analysis and anti-GFP 
immunostaining in MrgprdEGFP mice. We observed Mrgprd mRNA and Mrgprd protein expression 
in sensory DRG neurons projecting to the colon at a similar frequency to that observed in previous 
studies (51), thereby not only confirming the presence of a Mrgprd-positive colonic neuronal 
subtype, but also reinforcing Mrgprd as a potential target of 5-oxoETE. The activity of 5-oxoETE 
towards Mrgprd was attested to by its ability to induce an increase in [Ca2+]i in IB4-positive 
sensory neurons, but not in mouse neurons in which Mrgprd was knocked down by shRNA or in 
neurons from Mrgprd-deficient mice. Conversely, whereas Ca2+ transients were stimulated by 5-
oxoETE in CHO cells transfected with a plasmid expressing Mrgprd, CHO cells transfected with 
a control plasmid were not responsive to 5-oxoETE. 
 
Activation of Mrgprd inhibits a fraction of the total M-current, carried primarily by the KCNQ2/3 
K+ channel, contributing to an increase in the excitability of DRG neurons (52). Thus, Mrgprd 
activation by 5-oxoETE might promote the excitability of primary nociceptive afferents by KCNQ 
inhibition. Several groups have demonstrated that retigabine, a KCNQ2–5 opener, is effective in 
reducing neuropathic (53) and inflammatory pain (54). At the visceral level, retigabine reduces 
capsaicin-induced visceral pain and can inhibit noxious chemosensitivity in human tissue, 
suggesting that KCNQ channels play an inhibitory role in the transmission of visceral nociception 
(55, 56). Given that human sensory DRG neurons express Mrgprd and are activated by 5-oxoETE, 
we can speculate that 5-oxoETE modulates KCNQ channels through Mrgprd activation, leading 
to neuronal activation that contributes to the pain symptoms associated with IBS-C. Nevertheless, 
because OXER1 is expressed in human tissue, we cannot exclude the possibility that this receptor 
is activated by 5-oxoETE in human tissue. Together, our current findings build on our previous 
studies to suggest a pivotal role for PUFA metabolites in the visceral pain associated with IBS (4). 
Specifically, our study identifies 5-oxoETE with pro-nociceptive activity, as a hallmark of the IBS-
C subtype. 
 
Materials and methods 
Chemicals 
6-keto-prostaglandin F1 (6kPGF1), thromboxane B2 (TXB2), prostaglandin E2 (PGE2), 
prostaglandin A1 (PGA1), 8-iso prostaglandin A2 (8-iso PGA2), prostaglandin E3 (PGE3), 15-
deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), lipoxin A4 (LxA4), lipoxin B4 (LxB4), lipoxin A4 
deuterated (LxA4-d5), resolvin D1 (RvD1), resolvin D2 (RvD2), 7-maresin (7-MaR1), leukotriene 
B4 (LTB4), leukotriene B5 (LTB5), leukotriene B4 deuterated (LTB4-d4), 10(S),17(S)-protectin 
(PDx), 18-hydroxyeicosapentaenoic acid (18-HEPE), dihydroxy-eicosatetraenoic acid (5,6-
DiHETE), 15-hydroxyeicosatetraenoic acid (15-HETE) and 12-HETE, 8-HETE, 5-HETE, 5-
HETE-d8, 17-hydroxy-docosahexaenoic acid (17-HDoHE) and 14-HDoHE, 14,15-
epoxyeicosatrienoic acid (14,15-EET) and 11,12-EET, 8,9-EET, 5,6- EET, 5-oxoeicosatetraenoic 
acid (5-oxoETE) were purchased from Cayman Chemicals. 
 
Patients 
Patients (Table 1) were recruited from outpatient clinics of the Department of Medical and Surgical 
Sciences of the University of Bologna (Italy), and were included according to the Rome III criteria 
for IBS. Healthy controls (HCs) were asymptomatic subjects undergoing colonoscopy for 
colorectal cancer screening. In this group, we excluded subjects based on the presence of the 
following symptoms in the previous 12 months: abdominal discomfort or pain, bloating, and bowel 
habit changes. Exclusion criteria for both IBS and HC included major abdominal surgery, any 
organic syndrome, celiac disease (excluded by detection of anti-transglutaminase and anti-
endomysial antibodies), asthma, food allergy, or other allergic disorders. None of these patients or 
HCs were taking nonsteroidal anti-inflammatory drugs or any other anti-inflammatory drugs 
(including steroids, antihistamines, and mast cell stabilizers). Patients and HCs gave written 
informed consent. The study protocol was approved by the local Ethic Committee (64/2004/O/Sper 
and EM14/2006/O) and conducted in accordance with the Declaration of Helsinki. Patients 
underwent colonoscopy, and, in all cases, 6 mucosal biopsies were obtained from the proximal 
descending colon. One biopsy was sent to the pathology department for exclusion of microscopic 
colitis or other microscopic tissue abnormalities and 4 were used in other studies. One biopsy was 
snap-frozen in liquid nitrogen for lipid extraction and PUFA quantification for the purpose of our 
study. 
 
Lipid extraction 
Biopsies were crushed with a FastPrep-24 Instrument (MP Biomedicals) in 500 µL of Hanks’ 
balanced salt solution (HBSS, Invitrogen) and 5 µL of internal standard mixture (LxA4-d5, LTB4-
d4, and 5-HETE-d8 at 400 ng/mL in MeOH). After 2 crush cycles (6.5 m/s, 30 s), 10 µL were 
withdrawn for protein quantification and 300 µL of cold methanol were added. Samples were 
centrifuged at 1000 g for 15 min at 4 °C. Supernatants were collected, adjusted to 2 mL in H2O, 
and submitted to solid-phase extraction using HRX-50 mg 96-well (Macherey Nagel). Briefly, 
after plate conditioning, the sample was loaded at flow rate of 0.1 mL/min. After complete loading, 
the plate was washed with H2O/MeOH (90:10, 2 mL) and lipid mediators were eluted with MeOH 
(2 mL). Solvent was evaporated under nitrogen and samples were dissolved with MeOH and stored 
at -80 °C for liquid chromatography/tandem mass spectrometry measurements. 
 
Liquid chromatography/tandem mass spectrometry (LC-MS/MS) measurements 
6kPGF1, TXB2, PGE2, PGA1, 8-isoPGA2, PGE3, 15d-PGJ2, LxA4, LxB4, RvD1, RvD2, 7-
MaR1, LTB4, LTB5, PDx, 18-HEPE, 5,6-DiHETE, 15-HETE, 12-HETE, 8-HETE, 5-HETE, 17-
HDoHE, 14-HDoHE, 14,15-EET, 11,12-EET, 8,9-EET, 5,6-EET and 5-oxo-ETE were quantified 
in human biopsies (57). To simultaneously separate 28 lipids of interest and 3 deuterated internal 
standards, LC-MS/MS analysis was performed on an ultra high-performance liquid 
chromatography system (UHPLC, Agilent LC1290 Infinity) coupled to an Agilent 6460 triple 
quadrupole MS (Agilent Technologies) equipped with electro-spray ionization operating in 
negative mode. Reverse-phase UHPLC was performed using a ZorBAX SB-C18 column (Agilent 
Technologies) with a gradient elution. The mobile phases consisted of water, acetonitrile (ACN), 
and formic acid (FA) (75:25:0.1; v/v/v) (Solution A) and ACN, FA (100:0.1, v/v) (Solution B). 
The linear gradient was as follows: 0% Solution B at 0 min, 85% Solution B at 8.5 min, 100% 
Solution B at 9.5 min, 100% Solution B at 10.5 min and 0% Soution B at 12 min. The flow rate 
was 0.35 mL/min. The autosampler was set at 5°C and the injection volume was 5 µL. Data were 
acquired in Multiple Reaction Monitoring (MRM) mode with optimized conditions. Peak 
detection, integration, and quantitative analysis were performed with Mass Hunter Quantitative 
analysis software (Agilent Technologies). For each standard, calibration curves were built using 
10 solutions at concentrations ranging from 0.95 to 500 ng/mL. A linear regression with a weight 
factor of 1/X was applied for each compound. The limit of detection (LOD) and the limit of 
quantification (LOQ) were determined for the 28 compounds using signal to noise (S/N) ratios. 
The LOD corresponded to the lowest concentration leading to a S/N value > 3 and LOQ 
corresponded to the lowest concentration leading to a S/N value > 10. All values less than the LOQ 
were not considered. Blank samples were evaluated, and their injection showed no interference 
(no peak detected), during the analysis. Hierarchical clustering was performed and heat-maps were 
obtained with R (www.r-project.org). PUFA metabolite amounts were transformed to z-scores and 
clustered based on 1-Pearson correlation coefficient as distance and the Ward algorithm as 
agglomeration criterion. 
 
Animals 
C57BL/6 male mice (3 weeks-old) were purchased from Janvier. Mrgprdcre/+ mice were a generous 
gift from D. Anderson (Caltech, Pasadena). These mice were previously generated as described by 
Rau et al. (44) and were in an almost pure C57/Bl6J background when we received them at the 
IBDM (Institut de Biologie du Développement de Marseille) mouse facility. There, the mice were 
kept as heterozygotes and were backcrossed to C57/Bl6J for another 8 generations. Mrgprd-
deficient mice used in this study were obtained by intercrossing Mrgprdcre/+ heterozygous mice. 
Animals were maintained in ventilated cages (4 mice per cage) in a specific pathogen–free room 
at 20 to 24°C and relative humidity (40 to 70%) with a 12-hour light/dark cycle and given free 
access to food and water. Animal Care and ethic Committee of US006/CREFE (CEEA-122) 
approved the whole study protocol (permit No. MP/01/64/09/12). MrgprdEGFP mice (B6;129SP2-
Mrgprdtm4.1(COP4)Mjz/Mmnc; MMRRC, North Carolina, USA) were raised and maintained at the 
University of Glasgow and were characterized previously (58). Experiments conducted at the 
University of Glasgow were approved by the University’s Ethical Review Process Applications 
Panel and were performed in accordance with the European Community directive 86/609/EC and 
the United Kingdom Animals (Scientific Procedures) Act 1986. 
 
Measurement of somatic nociception 
Paw-withdrawal thresholds were measured using calibrated von Frey filaments with forces ranging 
from 0.04 to 2 g (Stoelting), which were applied onto the plantar surface of the mice. An ascending 
series of von Frey filaments was applied with each monofilament being tested 5 times for 
approximately 1 s. Threshold to mechanical stimuli was calculated as the force value of the von 
Frey filament triggering 3 paw withdrawals over 5 applications (59). Responses to mechanical 
stimuli were recorded before and 15 min, 30 min, 1 hour, 2 hours, and 6 hours after an intraplantar 
injection of 0.1, 1, 10, or 100 µM 5-oxoETE or vehicle (HBSS). In a second set of experiments, 
paw edema was measured using a digital caliper (resolution 0.01; Mitutoyo, Aurora, IL, USA) at 
1, 2, 3 and 4 hours after intraplantar injection of 100 µM 5-oxoETE. At the end of the experiment, 
paws were collected for histological analysis by hematoxylin and eosin (H&E) staining. 
 
Colorectal distension (CRD) and electromyography recordings 
Mice were administered either 100 μL of 5-oxoETE (10 µM) or vehicle (40% ethanol) 
intracolonically. We performed a session of CRD and recorded visceromotor responses (VMRs) 
from implanted electrodes before and 30 min after treatment as previously described (60). Data 
are presented as the difference between the VMR induced by the distension performed before and 
after intracolonic treatments. After distension, mouse colons were harvested to perform 
histological (H&E) analysis and myeloperoxidase activity assay. 
 
Lumbar splanchnic nerve recording 
The distal colon with associated lumbar splanchnic nerves was removed from male C57BL/6 mice 
(12 weeks old). The colon was then opened along the anti-mesenteric border and pinned flat, 
mucosal side up. The tissue was perfused (7 mL/min; 32 to 34℃) with carbogenated Krebs buffer 
(124 mM NaCl, 4.8 mM KCl, 1.3 mM NaH2PO4, 2.4 mM CaCl2, 1.2 mM MgSO4.7H2O, 11.1 mM 
glucose, 25 mM NaHCO3) and supplemented with 10 µM nifedipine and 10 µM atropine to block 
smooth muscle contraction, and 3 µM indomethacin to inhibit endogenous prostanoid production. 
Single unit activity was discriminated using wave form analysis software (Spike 2 Cambridge 
Electronic Design) from fibers teased from the lumbar splanchnic nerve (rostral to the inferior 
mesenteric ganglia), recorded using borosilicate glass suction electrodes. Signals were amplified, 
band pass filtered (gain 5K; 100-1300 Hz; Neurology, Digitiser Ltd, UK), digitally filtered for 
50Hz noise (Humbug, Quest Scientific, Canada), digitalised at 20 kHz (micro1401; Cambridge 
Electronic Design, UK), and displayed on a computer using Spike 2 software. Individual receptive 
fields of afferent nerve fibers were identified by systematically probing the tissue with a 1-g von 
Frey filament. Receptive fields that responded to probing and not to stretch were identified as 
serosal units (61). Once a serosal unit was identified, a metal ring was placed over the receptive 
field and the baseline activity was observed for 3 min. The Krebs solution within the ring was then 
removed and replaced by 100 µM 5-oxoETE pre-warmed to bath temperature. Following a 7-min 
challenge period, the 5-oxoETE and ring were removed. 
 
Immunofluorescence in mouse colon 
The descending colons of 10 WT and 10 Mrgprd-deficient mice were cryoprotected in OCT 
compound, sectioned at a thickness of 10 µm (one every 0.1 cm, 20 per mouse) on a cryostat (Leica 
CM1950, Nanterre, France), and mounted on Superfrost slides (Thermo Fisher Scientific, 
Villebonne-sur-Yvette, France). Slides were washed in phosphate-buffered saline (PBS), 0.5% 
Triton X-100, and 1% bovine serum albumin (BSA) solution (Sigma), and incubated overnight at 
4°C with anti-Mrgprd (1:500, AMR-061, Alomone labs, Clinisciences, Nanterre, France) and anti-
PGP9.5 (1:500, AB86808, Abcam, Coger SAS, Paris, France) as primary antibodies. After 
washing, slides were incubated with the appropriate secondary antibody conjugated with Alexa 
Fluor 488 or Alexa Fluor 555 (Thermo Fisher Scientific), washed, and mounted with ProLong 
Gold reagent containing DAPI (Molecular Probes). Images were acquired using a Zeiss LSM-710 
confocal microscopes (Carl Zeiss MicroImaging, Jena, Germany) with 20X objective in the 
inverted configuration. 
 
Single-cell qRT-PCR analysis of retrogradely labelled mouse sensory neurons 
DRG neurons projecting to the colon were selectively labelled and individually harvested by pulled 
glass pipette. After RNA extraction, single-cell RT-qPCR analysis for the presence of Mrgprd 
mRNA transcripts was performed as previously described (62). Briefly, adult mice were subjected 
to laparotomy under anesthesia and 6 to 8 injections of Fast Blue (~ 0.2 L, 2 % in saline; 
Polysciences GmbH) were made into the wall of the distal colon. Five days after surgery, 
thoracolumbar (TL; T10-L1) DRGs were collected and enzymatically dissociated (62). Individual 
cells were isolated by pulled glass pipette and collected into a preamplification mastermix 
containing 0.1 μL SUPERase-in (Ambion, TX, USA), 0.2 μL Superscript III Reverse 
Transcriptase/Platinum Taq mix (Invitrogen), 5 μL CellDirect 2x reaction buffer (Invitrogen), 2.5 
μL 0.2x primer/probe mix, and 1.2 μL TE buffer (Applichem, GmbH) before thermal cycling 
[50°C for 30 min, 95°C for 2 min, and then 21 cycles of (95°C for 15 s, 60°C for 4 min)]. TaqMan 
qPCR assays for Mrgprd (TaqMan Assay ID: Mm01701850_s1) and Trpv1 (Mm01246300_m1) 
were performed on diluted cDNA products (1:5 in TE buffer) using the following cycling protocol: 
50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of (95°C for 15 seconds, 60°C for 1 
minutes). Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) mRNA acted as an internal 
positive control and a sample of the bath solution was used as a no-template negative control. Sll 
single-cell RT-PCR products contained Gapdh mRNA, whereas bath control samples did not. The 
quantitative assessment of gene expression was determined by quantification of cycle (Cq) values 
less than the threshold of 35 that were considered as positive. In total, 15 single cells per spinal 
region (TL) per mouse (n = 3 mice) were isolated; therefore, the expression of mRNA transcripts 
was determined in 45 colonic sensory neurons. 
 
Immunohistochemistry of Fast Blue–labelled colonic sensory neurons from MrgprdEGFP mice 
From thoracolumbar regions, DRG T13 were stained from four MrgprdEGFP mice retrogradely 
labelled with Fast Blue to the colon, as described earlier. A single T13 DRG was sectioned 
sequentially across 10 slides at 12-µm thickness. Therefore, on a given slide, the T13 DRG was 
sampled at 120-µm intervals for the full thickness of the DRG. In total, 16 sections from 4 animals 
were analysed, yielding 274 Fast Blue–labelled cells. Slides were stained with chicken anti-GFP 
(1:1000; Abcam Ab13790) and rabbit anti-CGRP (1:10000, Sigma C8198) antisera. The secondary 
antibodies used were goat anti-chicken-488 (1:1000) and donkey anti-rabbit-594 (1:1000). Each 
probe (that is, MrgprdEGFP and CGRP) per section had a background reading subtracted and was 
normalized between the maximum and minimum intensity cells. A threshold of mean + 3 SD for 
the minimum intensity cells (from all 16 sections) was used to differentiate positive from negative 
cells. Positive cells were then manually confirmed. 
 
Ca2+ imaging of mouse sensory neurons 
DRGs of WT and Mrgprd-deficient mice were rinsed in cold HBSS (Invitrogen), and 
enzymatically dissociated as described previously (63). Neurons were plated in 96-well plates 
(fluorescence Greiner bio one, Domique Dutscher, Brumath, France) and cultured for 24 hours. In 
a first set of experiments, neurons were treated with 5-oxoETE (1, 5, 25, 50, and 100 µM) or 
vehicle (HBSS). In a second set of experiments, neurons were incubated for 1 hour with 10 µg/mL 
isolectin B4 from Griffonia simplicifolia conjugated to Alexa Fluor 594 (ThermoFisher) to 
differentiate IB4-positive from IB4-negative sensory neurons. Ca2+ flux was monitored by 
recording the changing emission intensity of Fluo-4 (Molecular probe) after treatment with 5-
oxoETE (10 µM) or vehicle. In a third set of experiments, neurons were pre-incubated with PTX 
(250 ng/mL) overnight or with the U73122 phospholipase C inhibitor (10 µM) 30 min before 
treatment with 5-oxoETE (50 µM) or vehicle. 
 
Expression of shRNA directed against Mrgprd in sensory neurons 
Lentiviral particles were produced as previously described (64). Briefly, HEK293T/17 cells 
(ATCC) were cultured according to the supplier’s recommendations. Cells (1.7x107) were seeded 
into a 175-cm2 culture flask containing 30 mL of DMEM (Gibco, USA) and then incubated at 
37°C 5% CO2. On the next day, cells were transfected with a mixture of structural (psPAX2 and 
pMD2.G; Addgene, Cambridge, MA, USA) and transfer vectors (shRNA Mrgprd-RFP-CB or the 
control shRNA-RFP-CB; OriGene Technologies), with GeneJuice (Millipore, USA) transfection 
reagent. Cells were incubated overnight at 37°C and 5% CO2 before the medium was replaced 
with 18 mL of OptiMEM (Gibco, USA). Cell culture medium were harvested 48 hours later and 
cleared by centrifugation and filtration with a 0.45-m syringe filter. Neurons were plated in 96-
well plates coated with poly-L-ornithine/laminin and cultivated in Neurobasal medium 
supplemented with B27 and L-glutamine before being transduced with 50 μL of lentiviral 
supernatant. Three days later, a transduction efficiency of 35% was achieved and a calcium flux 
assay was performed in response to 5-oxoETE (10 µM), as described earlier. 
 
Ca2+ flux in CHO cells expressing Mrgprd 
CHO cells were transfected with a plasmid expressing mouse Mrgprd (OriGene Technologies, 
Rockville, USA) with GeneJuice Transfection Reagent (1 μg of plasmid for 3 μL of GeneJuice). 
The cells were incubated in Ham’s F12 Nutrient Mixture with 5% of FBS. G418 (Sigma) was used 
as the selection antibiotic. Cells (50×103 cells/well) in a 96-well plate were incubated with fluo-8 
loading solution (Fluo-8-AM; Invitrogen) according to the manufacturer’s instructions. The 
fluorescence was then measured at 530 nm on a microplate reader (NOVOstar; BMG Labtech) for 
1 min. Five seconds after the beginning of the calcium measures, 5-oxoETE (1, 10, 25, 50, 100 
and 200 µM) or -alanine (Sigma-Aldrich; 1 mM) was added. Data were collected and analyzed 
with the NOVOstar software. 
 
Ca2+ imaging of human sensory neurons 
Experiments were conducted according to opinion number 14-164 of the institutional review board 
(IRB00003888) of the French institute of medical research and health. Three human T11 (thoracic 
position 11) DRGs were supplied through the national human tissue resource center from the 
national disease resource interchange (NDRI). The DRGs were received unfixed in DMEM at 4°C. 
DRGs were dissected, minced in HBSS, and incubated in Papain (27 µg/mL) (Sigma, Saint 
Quentin Fallavier, France) for 20 min at 37°C. After a wash with L-15 Wash Buffer [Leibovitz’s 
L-15 Medium (Invitrogen), 10% FBS (Invitrogen)] and HBSS, the DRGs were incubated in HBSS 
containing 1 mg/mL of collagenase type IV (Worthington, Lakewood, NJ, USA) and 4 mg/mL of 
dispase II (Sigma). L-15 Wash buffer was added to neutralize enzymatic activities and the 
suspension was centrifuged at 1000 g for 5 min. The cycle of digestion was repeated 3 times for 
15 min. Neurons in the pellet were suspended in Neurobasal medium (Invitrogen) containing 2% 
B27, 2 mmol/L glutamine, 1% penicillin/streptomycin, and 10 µM each of cytosine arabinoside, 
5-Fluoro-2′-deoxyuridine (FUDR), and Uridine (all from Sigma). The medium was changed every 
3 days without cytosine arabinoside. Cells were plated in CC2 LabTek II (Nunc, Domique 
Dutscher, Brumath, France) for the calcium signalling assay as described earlier in response to 5-
oxoETE (0.1, 1 and 10 µM) and for immunochemistry. 
 
Immunofluorescence in human dorsal root ganglia 
Experiments were performed according to opinion number 12-074 of the institutional review board 
(IRB00003888) of the French institute of medical research and health. Two human T11 (thoracic 
position 11) DRGs were supplied through the national human tissue resource center from the 
national disease resource interchange (NDRI). The DRGs were received unfixed and 
cryoprotected. The DRGs were cut into 20-µm sections on a cryostat (Leica CM1950, Nanterre, 
France), and mounted on Superfrost slides (Thermo Fisher Scientific, Villebonne-sur-Yvette, 
France). Cultured sensory neurons and slides were washed in PBS, 0.5% Triton X-100, and 1% 
BSA solution (Sigma, Saint-Quentin Fallavier, France) and incubated overnight at 4°C with anti-
Mrgprd (1:100, LS-A4123, LifeSpan Biosciences, Clinisciences, Nanterre, France) and anti-
PGP9.5 (1:500, AB86808, Abcam). After washing, the slides and cultured DRG were incubated 
with the appropriate secondary antibody conjugated with Alexa Fluor 488 or Alexa Fluor 555, 
washed, and mounted with ProLong Gold reagent containing DAPI (Molecular Probes). Images 
were acquired using a Zeiss LSM-710 confocal microscope (Carl Zeiss MicroImaging, Jena, 
Germany) with a 20X objective in the inverted configuration. 
 
Study approval 
The study protocol for biopsy collection was approved by the local Ethic Committee 
(64/2004/O/Sper and EM14/2006/O) and conducted in accordance with the Declaration of 
Helsinki. Patients and HCs gave written informed consent. Fixed and fresh human DRGs were 
supplied through the national human tissue resource center from the national disease resource 
interchange (NDRI, reference: DCEN1 001). Experiments on human DRGs were performed 
according to opinion number 14-164 of the institutional review board (IRB00003888) of the 
French institute of medical research and health. Animal experiments were conducted according to 
the European union council directive 2010/63/EU. The Animal Care and ethic Committee of 
US006/CREFE (CEEA-122) approved the whole study protocol (permit No. MP/01/64/09/12). 
Experiments conducted at the University of Glasgow were approved by the University’s Ethical 
Review Process Applications Panel and were performed in accordance with European Community 
directive 86/609/EC and the United Kingdom Animals (Scientific Procedures) Act 1986. 
 
Statistical analysis 
Data are presented as means ± standard error of the mean (SEM). Analyses were performed using 
GraphPad Prism 5.0 software (GraphPad, San Diego, CA). Comparisons between groups were 
performed by Mann-Whitney test. Multiple comparisons within groups were performed by 
Kruskal-Wallis test, followed by Dunn’s post-test. Statistical significance was accepted at P < 
0.05. 
 
Supplementary Materials 
Fig. S1. Concentrations of PUFA metabolites in biopsies from patients with IBS. 
Fig. S2. Concentrations of PUFA metabolites in biopsies of all IBS patients. 
Fig. S3. 5-oxoETE does not induce somatic or visceral inflammation in vivo. 
Fig. S4. 5-oxoETE induces Ca2+ flux in mouse sensory neurons. 
Fig. S5. Mrgprd immunoreactivity is observed in mouse colon. 
Fig. S6. Mrgprd immunoreactivity is not observed in the colon of Mrgprd-deficient mice. 
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Fig. 1. Quantification of PUFA metabolites in mucosa of IBS patients. (A) Heat-map of PUFA 
metabolites quantified by liquid chromatography-tandem mass spectrometry. Data are shown in a 
matrix format: each row represents a single PUFA metabolite, and each column represents a 
subgroup of patients. Each color patch represents the normalized quantity of PUFA metabolites 
(row) in a subgroup of patients (column), with a continuum of quantity from bright green (lowest) 
to bright red (highest). The pattern and length of the branches in the dendrograms reflect the 
relatedness of the PUFA metabolites. The dashed red line is the dendrogram distance used to 
cluster PUFA metabolites. (B) 5-oxoETE quantified by liquid chromatography-tandem mass 
spectrometry in the mucosa of HCs (white circle) and patients with the indicated type of IBS (black 
circle). Data are expressed in pg/mg protein and presented as means ± SEM of 10 to 20 biopsies 
per group. Statistical analysis was performed using Kruskal-Wallis analysis of variance and 
subsequent Dunn’s post hoc test. ***P < 0.001 compared to the HC group. 
 
Fig. 2. 5-oxoETE induces somatic and visceral hypersensitivity in vivo. (A to E) Eight-week-
old male C57BL/6J mice were subcutaneously injected with either HBSS (white circle) or 5-
oxoETE (black circle) into hind footpads. (A) Somatic pain was monitored using the von Frey test 
at the indicated times after injection with 10 µM 5-oxoETE or HBSS. Data are means of three 
independent experiments with 5 mice per group. Errors bars indicate SEM. (B) The Von Frey test 
was performed 30 min after injection of the indicated concentrations of 5-oxoETE. Data are means 
± SEM of two experiments with six mice per group. (C) Mouse paw tissue samples were stained 
with H&E 6 hours after the administration of HBSS or 100 µM 5-oxoETE as indicated. Images 
are representative of two experiments with 5 mice per group. (D) Visceromotor response (VMR) 
to increasing pressures of colorectal distension before and 30 min after intracolonic administration 
of 10µM 5-oxoETE (black bars) or vehicle (40% ethanol; white bars). Data are means ± SEM of 
two experiments with 10 mice per group and are relative to the baseline recorded before treatment. 
(E) Colon tissue samples stained with H&E from mice treated with 40% ethanol or 10 µM 5-
oxoETE as indicated. Images are representative of two experiments with 5 mice per group. 
Statistical analysis was performed using Kruskal-Wallis analysis of variance and subsequent 
Dunn’s post hoc test. **P < 0.01, ***P < 0.001, compared to control mice. 
 
Fig. 3. 5-oxoETE induces lumbar splanchnic nerve firing. (A) Example of a teased-fiber 
recording showing the lumbar splanchnic (that is, colon-innervating) nerve response to ring 
application (7 min) of 5-oxoETE in mouse serosal afferents. Arrows indicate application and 
removal of 5-oxoETE. Data are representative of eight experiments in which 5-oxoETE elicited 
nerve discharge above baseline from a total of 21 teased fibers isolated from 7 mice. (B) Mean 
change in firing/s in serosal receptive fields in response to 5-oxo-ETE compared with the response 
to vehicle (Krebs buffer). Data are means ± SEM of 8 teased-fiber recordings (N = 7 mice) for 5-
oxoETE and 5 teased-fiber recordings (N = 5 mice) for vehicle. Statistical analysis was performed 
using a Mann-Whitney t-test. **P < 0.01 compared to vehicle. (C) Proportion of responses in 
lumbar splanchnic afferents to application of 5-oxoETE (n, number of teased-fiber recordings; N, 
number of mice). 
 
Fig. 4. 5-oxoETE induces an increase in [Ca2+]i in sensory neurons through a GPCR. (A) 
Representative trace of Ca2+ flux experiments in sensory neurons incubated in the absence of 
extracellular Ca2+/Mg2+ and exposed to 50 µM 5-oxoETE or vehicle (HBSS). (B) Ca2+ flux 
measurements in mouse sensory neurons exposed to the indicated concentrations of 5-oxoETE 
(black circle) or to vehicle (HBSS; white circle). Data are means + SEM of seven independent 
experiments with 3 wells per condition and 60 to 80 neurons per well. (C) Amplitude of [Ca2+]i 
(F/F; left) in human sensory neurons and the percentage of responding neurons (right) exposed 
to the indicated concentrations of 5-oxoETE (black bar) or to vehicle (HBSS; white bar). Data are 
means ± SEM of three independent experiments with 3 wells per condition and 20 to 53 neurons 
per well. (D) Percentages of isolectin B4–positive (IB4+) and IB4-negative (IB4-) mouse sensory 
neurons that responded to 10 µM 5-oxoETE (black bars) or HBSS (white bars). Data are means ± 
SEM of three independent experiments with 3 wells per condition and 60 to 80 neurons per well. 
(E) Effects of 30-min incubation with 10 μM U73122 (PLC inhibitor) or overnight incubation with 
PTX (250 ng/ml) on 5-oxoETE–induced Ca2+ mobilization in mouse sensory neurons. Data are 
means ± SEM of five independent experiments with 3 wells per condition and 60 to 80 neurons 
per well. Statistical analysis was performed using Kruskal-Wallis analysis of variance and 
subsequent Dunn’s post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 compared to HBSS. 
 
Fig. 5. Expression of Mrgprd in sensory neurons. (A) Expression of Mrgprd (red) and Trpv1 
(blue) mRNA transcripts as detected by single-cell qRT-PCR analysis (middle) of retrogradely 
labelled mouse colonic sensory neurons (left). Pie chart representation (right) of the expression 
(dark color) or not (light color) of Mrgprd and Trpv1 mRNA in Fast Blue (FB)-positive neurons. 
Each segment represents a single colonic sensory neuron. (B) Representative images of GFP 
(green), CGRP-immunoreactivity (red), and FB labelling (blue) in a T13 DRG from a MrgprdEGFP 
mouse in which FB was injected into the colon. Scale bar, 50 µm. Inset images are magnifications 
of the boxed areas in the largest images. (C and D) Expression of Mrgprd by immunostaining in a 
whole human T11 DRG (C) and in a primary culture of human sensory neurons using confocal 
microscopy (D). Pie chart representation of the immunoreactivity (dark color) or not (light color) 
of Mrgprd in Pgp9.5-positive neurons. Each segment represents a single sensory neuron. Scale 
bars, 10 µm. Images are representative of 2 experiments with 10 slides per experiment (C) and of 
5 experiments with 2 wells per experiment (D). 
 
Fig. 6. Mrgprd expression is required for the intracellular Ca2+ mobilization and 
hypersensitivity induced by 5-oxoETE. (A) Left: Representative image of sensory neurons 
transfected with shRNA (red) and containing the Ca2+ indicator Fluo4 (green). Right: Percentage 
of sensory neurons expressing control shRNA or Mrgprd-specific shRNA that responded to HBSS 
or 10 µM 5-oxoETE. Data are means ± SEM of six independent experiments with 3 wells per 
conditions and 10 to 32 analyzed neurons per well. (B) Percentage of responding neurons (left) 
and amplitude of intracellular Ca2+ mobilization (F/F; right) in mouse sensory neurons from 
Mrgprd-deficient mice exposed to vehicle (HBSS; white bar), 10 µM 5-oxoETE (black bar), or to 
a mixture of GPCR agonists (GPCR Mix: bradykinin, serotonin, and histamine, 10 µM each; gray 
bar). Data are means ± SEM of four independent experiments with 3 wells per condition and 20 to 
50 neurons per well. (C) Effects of the indicated concentrations of 5-oxoETE and of 1 mM -
alanine (positive control) on the amplitude (F/F) of Ca2+ mobilization in HEK cells transiently 
transfected with plasmid expressing Mrgprd or with an empty vector as a control. Data are means 
± SEM of eight independent experiments with 3 wells per condition. (D) Visceromotor response 
(VMR) in Mrgprd-deficient mice in response to increasing pressures of colorectal distension 
before (baseline; white circle) and 30 min after intracolonic administration of 10 µM 5-oxoETE 
(black circle). Data are means + SEM of two experiments of 7 mice per experiment. Statistical 
analysis was performed using Kruskal-Wallis analysis of variance and subsequent Dunn’s post 
hoc test. In (A), **P < 0.01 compared to the control shRNA/HBSS group; In (B), **P < 0.01 
compared to the HBSS group; In (C), *P < 0.05, **P < 0.01, ***P < 0.001 compared to the 
corresponding CHO empty vector group. 
  
Table 1. Characteristics of patients from which biopsies were collected for the quantification 
of PUFA metabolites. 
 
 Control IBS 
Number 14 50 
Age 49 (20-76) 43 (20-72) 
Sex ratio (F/M) 8/6 32/18 
Bowel movements:   
Diarrhea 0 20 
Constipation 0 20 
Mix 0 10 
 
  
Table 2. Percentage of Fast Blue–positive neurons expressing Mrgprd, CGRP, or both in T13 
DRGs per MrgprdEGFP mouse. 
 
Animal Mrgprd+ CGRP+ Mrgprd+ and CGRP+ 
A 9 / 75 (12.0%) 54 / 75 (72.0%) 0 / 75 (0.0%) 
B 2 / 38 (5.3%) 24 / 38 (63.2%) 0 / 38 (0.0%) 
C 10 / 101 (9.9%) 64 / 101 (63.4%) 1 / 101 (1.0%) 
D 1 / 60 (1.7%) 46 / 60 (76.7%) 0 / 60 (0.0%) 
Total (mean ± SD) 7.2 ± 4.6 % 68.8 ± 6.7 % 0.3 ± 0.5 % 
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